Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Conditions

• Non-small Cell Lung Cancer

Interventions

• OTHER: Erlotinib w Concurrent Radiotherapy
• OTHER: etoposide/cis-platin (EP) w Concurrent Radiotherapy

Sponsor

Jinming Yu

Collaborators

• [object Object]